Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com 3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com 3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com 4 years ago
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
@xconomy.com 4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com 5 years ago
Former Zavante Executive Tapped as Abide Therapeutics President
@xconomy.com 5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@techcrunch.com 5 years ago
CB Therapeutics’ lab-grown cannabinoids could unlock new medicines and make others affordable
@xconomy.com 5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@venturebeat.com 6 years ago
Relay Therapeutics Secures $63 Million in Series B Financing